search for a cure of hiv/aids dr. yuntao wu depatment of molecular and microbiology george mason...
Post on 01-Apr-2015
213 Views
Preview:
TRANSCRIPT
Search for a cure of HIV/AIDS
Dr. Yuntao Wu
Depatment of Molecular and MicrobiologyGeorge Mason University, Manassas, VA
Early History of AIDS
• In March 1981, at least 8 cases of Kaposi’s Sarcoma (KS) have occurred amongst young gay man in New York.
• By April, CDC noticed an increase in PCP (pneumocystis carinii pneumonia).
• In June, CDC published a report about PCP in 5 men in Los Angeles. Then, CDC formed a Task Force on KS and Opportunistic Infections.
• In July, CDC reported KS in 26 gay men in New York City.
• Between June 1st - May 28, CDC received 355 KS/PCP reports, 79% were homosexual
• The disease were initially called GRID:
Gay-Related Immune Deficiency
- In July 1982, first non-homosexual case reports appeared that the disease was occurring in Haitians and Haemophiliacs.
- In the same month, AIDS was suggested in a meeting in Washington DC.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
From http://aidshistory.nih.gov/first_encounters/back.html
The purplish lesions of Kaposi's sarcoma, a cancer not usually seen in young men, were common among the patients with the new immune deficiency disease.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
http://www.visualdxhealth.com/child/oralCandidiasisThrush-signsAndSymptoms.htm
Thrush: Oral Candidiasis
The Discovery of the AIDS Virus - HIV in 1983
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
Luc MontagnierHIV-1LAV(HIV-1Lai/LAV)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
Robert GalloHTLV-IIIB(HIV-1Lai/IIIB)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
Jay A LevyUCSF
Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)
• F. Barre-Sinoussi; J. C. Chermann; F. Rey; M. T. Nugeyre; S. Chamaret; J. Gruest; C. Dauguet;C. Axler-Blin; F. Vezinet-Brun; C. Rouzioux; W. Rozenbaum; L. Montagnier
• Science, New Series, Vol. 220, No. 4599. (May 20, 1983), pp. 868-871.
HIV-1
gp120gp41
p17
p24
RT
IN
RNA
PR
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.Nef
• What is AIDS ?
(Acquired Immunodeficiency Syndrome)
1993 CDC revised definition:
HIV-1 infected persons who have less than 200 CD4 T cells per ul or a CD4 percentage of total lymphocytes of less than 14%. 26 clinical conditions
Candidiasis of bronchi, trachea, or lungsCandidiasis, esophagealCervical cancer, invasive *Coccidioidomycosis, disseminated or extrapulmonaryCryptococcosis, extrapulmonaryCryptosporidiosis, chronic intestinal (greater than 1 month's duration)Cytomegalovirus disease (other than liver, spleen, or nodes)Cytomegalovirus retinitis (with loss of vision)Encephalopathy, HIV-relatedHerpes simplex: chronic ulcer(s) (greater than 1 month's duration); or bronchitis, pneumonitis, or esophagitisHistoplasmosis, disseminated or extrapulmonaryIsosporiasis, chronic intestinal (greater than 1 month's duration)Kaposi's sarcomaLymphoma, Burkitt's (or equivalent term)Lymphoma, immunoblastic (or equivalent term)Lymphoma, primary, of brainMycobacterium avium complex or M. kansasii, disseminated or extrapulmonaryMycobacterium tuberculosis, any site (pulmonary * or extrapulmonary)Mycobacterium, other species or unidentified species, disseminated or extrapulmonaryPneumocystis carinii pneumoniaPneumonia, recurrent *Progressive multifocal leukoencephalopathySalmonella septicemia, recurrentToxoplasmosis of brainWasting syndrome due to HIV
The Possible Origins of HIV-1
- likely transmitted to man from chimpanzees infected with SIVcpz in West Africa. However, Chimpanzees may not be the original reservoir Pan troglodytes
The Possible Origin of HIV-2
- likely transmitted to man from SIVsmm-infected sooty mangabeys in west Africa
Adults and children estimated to be living Adults and children estimated to be living with HIVwith HIV
Total: 37.8 (34.6 – 42.3) million
Western Europe580 000580 000
[460 000 – 730 000][460 000 – 730 000]
North Africa & Middle East
480 000480 000[200 000 – 1.4 million][200 000 – 1.4 million]
Sub-Saharan Africa25.0 million25.0 million
[23.1 – 27.9 million][23.1 – 27.9 million]
Eastern Europe & Central Asia1.3 million 1.3 million [860 000 – [860 000 – 1.9 million]1.9 million]
South & South-East Asia
6.5 million6.5 million[4.1 – 9.6 million][4.1 – 9.6 million]
Oceania32 00032 000
[21 000 – 46 000][21 000 – 46 000]
North America1.0 million1.0 million
[520 000 – 1.6 million][520 000 – 1.6 million]
Caribbean430 000430 000
[270 000 – 760 000][270 000 – 760 000]
Latin America1.6 million1.6 million
[1.2 – 2.1 million][1.2 – 2.1 million]
East Asia900 000900 000
[450 000 – 1.5 million][450 000 – 1.5 million]
Clinic Course of HIV Infection
G. Pantaleo, C. Graziosi, and A.S. Fauci 1993a.. N. Engl. J. Med. 328: 327-335.
HIV Replication Cycle
RNA
DNA
RT
tat,rev,nef
Env,vif,vpr,vpu
gag,pol
Transcription
Integrationrev
tatnef
CD4CXCR4
or CCR5
Reverse Transcriptase Inhibitor
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
by D
an S
t ow
el l
©2
00
2- 2
00
5) .
Zidovudine (AZT), Tenofovin, ddI, ddC, d4T
nucleoside analogues
Non-nucleoside analogues
Nevirapine, Delavirdine, TMC-120, TMC-125
from Goff, Fields Virology, 4th edition
1. 3’-end processing (cytoplasm)
2. Cleavage of cell DNA (nucleus)
3. Strand-transfer4. Gap filling
-5-bp direct repeat of cellular DNA
- dinucleotides: 5’-TG; 3’-CA
Model of HIV genomic packaging
From M. F. Summers
HAART
Highly Active Anti-Retroviral Therapy (HAART) consists of 3 or more highly potent anti-HIV drugs, commonly reverse transcriptase inhibitors and protease inhibitors.
a single drug therapy may be successful for a while, but because HIV changes to avoid detection, drug-resistant strains will often arise in the patient.
The chances of a HIV genome mutating such that it can resist three separate drug treatments at once, however, is so small that the pressure of this therapy prevents the emergence of resistant strains
QuickTime™ and a decompressor
are needed to see this picture.
QuickTime™ and a decompressor
are needed to see this picture.
QuickTime™ and a decompressor
are needed to see this picture.
QuickTime™ and a decompressor
are needed to see this picture.
QuickTime™ and a decompressor
are needed to see this picture.
QuickTime™ and a decompressor
are needed to see this picture.
HIV reservoirs
CD4 T cells- post-integration latency mostly in memory CD4 T cells- no active or low level active viral replication- rapidly generate viruses upon stimulation
Macrophages - tissue and brain macrophages, monocytes- resist to HIV mediated cell killing- actively generating virus in the body for a long period of time
Current Strategy to activate latent viral reservoirs
QuickTime™ and a decompressor
are needed to see this picture.
HDAC inhibitors
QuickTime™ and a decompressor
are needed to see this picture.
QuickTime™ and a decompressor
are needed to see this picture.
Histon Deacetylase Inhibitors
Limitations of re-activation strategy
1) Viral reservoirs in the body is not currently well-identified and understood
2) Not every latent virus can be re-activated by a single method
3) Reactivation does not lead to the elimination of latent cells
A “trojan horse” strategy to identify and eliminate HIV positive cells
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
The making of the “trojan horse”
5’ LTR
rev
tat
gag pol env nefvpu
vif
3’ LTRD1 A5D4 A7
X X X
X
X
XXX
vprX
HIV-1 Rev-dependent gene expression
gp160, Pr55
tat, rev, nef
env, vif, vpu, vpr
gag-pol
Rev
Tat, Rev, Nef
gp160, Pr55
mRNA
The Rev-dependent lentiviral vector: pNL-GFP-RRE
Rev
Procedure for generating lentiviral particles
pMD.G(VSV)
pCMV∆R8.2
pNL-GFP-RRE293T cells
1. HIV-1(AD8) infection of macrophages
2. Super-infection with vNL-GFP-RRE +
vNL-GFP-RRE
HIV-1(NL43.HSA) + vNL-GFP-RRE
GF
PmCD24
High specificity of the Rev-dependent vector
NIH AIDS Research & Reference Reagent Program: Cat # 11466Email: ywu8@gmu.eduPhone: 703-993-4299
Rev-dependent vectors carrying toxins andpro-apoptotic genes for targeting HIV-positive cells
• Anthrolysin O• Diphtheria toxin A chain• Human TRAF-6
- secreted by Bacillus anthracis- pore-forming, cholesterol-dependent cytolysin- lethal to to human primary monocytes, macrophages- cytotoxic activity is sensitive to the inhibition by cholesterol or serum
Anthrolysin O (AnlO)
Diphtheria toxin
EF2 + NAD+ ADPR-EF2 + nicotinamide + H+DT
- DT is an ADP ribosylating enzyme- the most studied bacterial toxin- ADP ribosylation occurs at one modified histidine in EF2- highly toxic, one molecule can kill a cell- multiple previous animal and human clinical trials using DT-A for cancer therapy and immuno-therapy to kill T cellsP
rote
in S
ynth
esi
s
Time
Diphtheria Toxin
QuickTime™ and a decompressor
are needed to see this picture.
- endogenous human gene- low level expression is tolerated and my help viral gene expression- over-expression trigger’s apoptosis- may not be as effective as bacterial toxins- safer to use than bacterial toxins
Tumor necrosis factor-associated factor 6 (TRAF6)
Killing efficiency:DT = 100%, TRAF6 = 86%, AlnO = 55%
DT-A mutants with reduced cytotoxicity
DT-A = 100%E18S = 96%E148D = 93%G128D = 65%DT∆N = 52%
Difficulties in assembly of lentiviral particles carrying toxins
pMD.G(VSV)
pCMV∆R8.2
pNL-GFP-RRE-(SA) 293T cells
Cloning and Mutagenesis of human EF-2 gene
*GGA CGAGly Arg
5H7, 46%
CB2, 28%
AB1, 24%
4H10, 14%
5E12, 9%
293T, 0%
From about 100 clones5 were DT-resistant
Resistance of 293T cells to TRAF-6
HeLa
GFP TRAF-6
0.0% 53%
24% 0.5%
7.6%
293T
0.0% 39% 25%
Cell control
Production of lentiviral particles carrying AnlO, DT-A and TRAF6
DNA construct Producer cell
p24 level at 48 hours post cotransfection
p24 level at 72 hours post cotransfection
pNL-TRAF6-RRE pCMV∆R8.2 pHCMV-G
HEK293T
1095 ng/ml
1659 ng/ml
pNL-AlnO-RRE pCMV∆R8.2 pHCMV-G
HEK293T + 6-BOCD
800 ng/ml
1500 ng/ml
pNL-DT∆N-RRE pCMV∆R8.2 pHCMV-G
5H7
109 ng/ml
102 ng/ml
Proof-of-concept: killing of HIV-positive macrophages in vitro
Proof-of-concept: killing of HIV-positive T cells in vitro
Limitations of the vector
1. Lack of selective entry
4. Toxin contamination of particles
2. Lack of ability to target resting CD4 T cells
5. Are they really safe ?
3. Integration-mediated mutagenesis
- need safety test in animals
Are these toxin particles really safe to inject ?
QuickTime™ and a decompressor
are needed to see this picture.
New York to DC
QuickTime™ and a decompressor
are needed to see this picture.
Acknowledgements NIAID: AI069981, AI081568 NINDS: NS051130NYCDC AIDS ride
GMU:Jessica YoungZhong-wei TangYangfan ZhengDongyang YuJeremy KellyMark SpearQuan YuBarney BishopSub IyerVladimir KarginovSerguei PopovTaissia Popova
NIH:Jon MarshDavid Neville
Harvard Medical School:Zhirui Wang
Zhong wei
top related